Streetbeat News

INCR

InterCure Ltd.

https://www.intercure.co

Industry

Drug Manufacturers - Specialty & Generic

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Open

1.44

Mkt cap

66M

Volume

38K

High

1.47

P/E Ratio

-3.60

52-wk high

3.72

Low

1.44

Div yield

N/A

52-wk low

1.17

Microsoft shares rise as the company reports better-than-expected Q1 2025 GAAP EPS and sales.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:05 pm

Banzai has been granted an extension by the Nasdaq Hearing Panel to regain compliance with listing requirements.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:34 pm

InterCure Ltd. (NASDAQ:INCR) has shown resilience in H1 2024 with revenues surpassing estimates despite challenges. The company is guiding for double-digit sales growth in H2 2024 and plans to expand its product offerings. However, cash reserves have plummeted, and net debt has increased. The stock has dropped significantly but remains attractively valued.

Portfolio Pulse from Nicolás Jose Rodriguez

September 14, 2024 | 6:32 pm

InterCure Ltd. (NASDAQ:INCR) reported a decline in revenue for the first half of 2024 due to damages from a terror attack but maintained profitability. The company is expanding its partnership with Cookies in Germany and expects double-digit growth in the second half of 2024. InterCure's shares rose by 2.47% following the announcement.

Portfolio Pulse from Nina Zdinjak

August 30, 2024 | 5:08 pm

Intercure shares are trading higher following the release of their H1 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 12:14 pm

InterCure's H1 2024 revenue decreased due to damages from a terrorist attack and war, but they are receiving compensation from Israeli authorities. They are expanding their partnership with Cookies™ to Germany and expect growth in H2 2024.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:13 am

European cannabis companies are planning IPOs on Nasdaq, driven by potential regulatory changes in the US and Germany. Companies like Grow Group, Somai Pharmaceuticals, and Wellford Medical are eyeing Nasdaq listings. US companies Curaleaf and Trulieve could benefit from tax breaks if cannabis is rescheduled to Schedule III. IM Cannabis and InterCure are also poised for growth in the European market.

Portfolio Pulse from Nicolás Jose Rodriguez

July 18, 2024 | 7:25 pm

InterCure (NASDAQ:INCR) is poised for significant growth due to potential U.S. cannabis rescheduling and expanding demand in Germany. Despite recent disruptions, the company is expected to rebound with double-digit growth in 2024. InterCure's strategic value lies in its expertise in pharmaceutical cannabis and its ability to produce quality products at scale. The company is expanding internationally, with plans to enter the German market by mid-2024 and potential acquisitions in Australia.

Portfolio Pulse from Nicolás Jose Rodriguez

May 24, 2024 | 8:13 pm

InterCure reported its full-year 2023 revenue at NIS 356 million.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 12:55 pm

InterCure announced its preliminary 2023 revenue of NIS 351 million and EBITDA of over NIS 50 million. This financial update is significant for investors tracking the company's performance.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.